

Examination of time action curves suggest that Wy-16,225 has a somewhat more rapid onset than morphine and shorter duration of action (Fig. 8). Wy-16,225 was identified predominantly as an opiate (Table 5), produced a typical pattern of opiate-like symptoms and signs (Table 6) and produced dose-related increases on the various scales measuring morphine-like effects (Fig. 9). Relative potencies from these dose response curves indicated that Wy-16,225 was approximately equipotent to morphine (Fig. 9).




Figure 8. Time action curves for the comparison of Wy-16,225, morphine and placebo. Each point represents the mean response. The response to morphine, 15 mg, and Wy-16,225, 15 mg, doses were omitted.